Patient-Reported Outcomes as Interradiographic Predictors of Response in Non-Small Cell Lung Cancer

Purpose: Minimally invasive biomarkers have been used as important indicators of treatment response and progression in cancers such as prostate and ovarian. Unfortunately, all biomarkers are not prognostic in all cancer types and are often not routinely collected. Patient-reported outcomes (PRO) provide a non-obtru-sive, personalized measure of a patient's quality of life and symp-tomatology, reported directly from the patient, and are increasingly collected as part of routine care. Previous literature has shown correlations between specific PROs (i.e., insomnia, fatigue) and overall survival. Although promising, these studies often only consider single time points and ignore patient-specific dynamic changes in individual PROs, which might be early predictors of treatment response or progression.Experimental Design: In this study, PRO dynamics were ana-lyzed to determine if they could be used as interradiographic predictors of tumor volume changes among 85 patients with non-small cell lung cancer undergoing immunotherapy. PRO questionnaires and tumor volume scans were completed biweekly and monthly, respectively. Correlation and predictive analysis were conducted to identify specific PROs that could accurately predict patient response.Results: Changes in tumor volume over time were significantly correlated with dizziness (P < 0.005), insomnia (P < 0.05), and fatigue (P < 0.05). In addition, cumulative changes in insomnia could predict progressive disease with a 77% accuracy, on average 45 days prior to the next imaging scan.Conclusions: This study presents the first time that patient-specific PRO dynamics have been considered to predict how individual patients will respond to treatment. This is an important first step in adapting treatment to improve response rates.

Automated summary

This study analyzed the dynamics of patient-reported outcomes (PROs) to predict tumor volume changes in non-small cell lung cancer patients undergoing immunotherapy. The study found significant correlations between changes in tumor volume over time and dizziness, insomnia, and fatigue. Cumulative changes in insomnia were able to predict progressive disease with 77% accuracy, an average of 45 days prior to the next imaging scan.